Scarica l'app Stockscreener
27.84
0.04%
-0.01
Pre-mercato:
27.94
0.10
+0.36%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché IMVT Giù?
Forum
Previsione
Precedente Chiudi:
$27.85
Aprire:
$28.27
Volume 24 ore:
1.05M
Relative Volume:
0.74
Capitalizzazione di mercato:
$5.67B
Reddito:
-
Utile/perdita netta:
$-464.20M
Rapporto P/E:
-10.38
EPS:
-2.6823
Flusso di cassa netto:
$-423.09M
1 W Prestazione:
+3.15%
1M Prestazione:
+13.63%
6M Prestazione:
+17.97%
1 anno Prestazione:
+82.92%
Intervallo 1D:
$27.14
$28.59
Intervallo di 1 settimana:
$26.13
$28.59
Portata 52W:
$13.36
$30.09
Immunovant Inc Stock (IMVT) Company Profile
Nome
Immunovant Inc
Settore
Industria
Telefono
917-410-3120
Indirizzo
1000 PARK FORTY PLAZA, DURHAM, NY
Compare IMVT vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IMVT
Immunovant Inc
|
27.84 | 5.67B | 0 | -464.20M | -423.09M | -2.6823 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Immunovant Inc Stock (IMVT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-20 | Iniziato | Bernstein | Mkt Perform |
| 2026-01-06 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2025-10-14 | Iniziato | Truist | Hold |
| 2025-07-10 | Ripresa | Goldman | Neutral |
| 2025-03-03 | Iniziato | Jefferies | Hold |
| 2025-01-03 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-10-09 | Reiterato | Oppenheimer | Outperform |
| 2024-03-28 | Iniziato | Oppenheimer | Outperform |
| 2024-03-13 | Iniziato | Goldman | Buy |
| 2024-02-20 | Iniziato | JP Morgan | Overweight |
| 2024-02-15 | Iniziato | Wolfe Research | Outperform |
| 2023-12-12 | Iniziato | Deutsche Bank | Buy |
| 2023-10-13 | Aggiornamento | UBS | Neutral → Buy |
| 2023-09-26 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2023-05-01 | Iniziato | BofA Securities | Buy |
| 2023-04-25 | Iniziato | Citigroup | Buy |
| 2023-03-31 | Iniziato | Piper Sandler | Overweight |
| 2023-03-30 | Iniziato | Stifel | Buy |
| 2023-02-15 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-02-13 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-01-03 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2022-09-26 | Downgrade | UBS | Buy → Neutral |
| 2021-12-08 | Iniziato | Wells Fargo | Equal Weight |
| 2021-08-03 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2021-08-02 | Downgrade | Credit Suisse | Neutral → Underperform |
| 2021-06-01 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-06-01 | Downgrade | Stifel | Buy → Hold |
| 2020-10-28 | Iniziato | UBS | Buy |
| 2020-10-12 | Iniziato | Guggenheim | Buy |
| 2020-10-08 | Iniziato | Stifel | Buy |
| 2020-10-02 | Iniziato | Credit Suisse | Outperform |
| 2020-08-26 | Reiterato | H.C. Wainwright | Buy |
| 2020-08-25 | Iniziato | Raymond James | Outperform |
| 2020-07-29 | Iniziato | H.C. Wainwright | Buy |
| 2020-02-24 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Immunovant Inc Borsa (IMVT) Ultime notizie
700,464 Shares in Immunovant, Inc. $IMVT Bought by Jennison Associates LLC - MarketBeat
Immunovant, Inc. $IMVT Shares Sold by Pictet Asset Management Holding SA - MarketBeat
Immunovant, Inc. (NASDAQ:IMVT) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
Trading Systems Reacting to (IMVT) Volatility - Stock Traders Daily
Immunovant's treatment for eye disease fails in late-stage trials - MSN
Immunovant director Robert Susman sells $67,979 in stock By Investing.com - Investing.com Nigeria
Immunovant director Robert Susman sells $67,979 in stock - Investing.com
Immunovant (IMVT) director’s 10b5-1 sale leaves 36,394 shares held - Stock Titan
Immunovant | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
[144] Immunovant, Inc. SEC Filing - Stock Titan
Alto Neuroscience, Immunovant and other big stocks moving lower in Thursday's pre-market session - MSN
Immunovant falls on late-stage trial setback for TED therapy - MSN
Wells Fargo Maintains Immunovant(IMVT.US) With Buy Rating, Maintains Target Price $45 - Moomoo
Wall Street analysts predict a 55.04% upside in Immunovant (IMVT): Here's what you should know - MSN
Immunovant (NASDAQ:IMVT) CFO Tiago Girao Sells 25,760 Shares - MarketBeat
Immunovant CFO Tiago Girao sells $763,011 in company stock By Investing.com - Investing.com India
Immunovant (NASDAQ:IMVT) CTO Sells $81,573.48 in Stock - MarketBeat
Immunovant CFO Tiago Girao sells $763,011 in company stock - Investing.com
Immunovant (IMVT) CFO sells 25,760 shares to cover RSU tax - Stock Titan
Immunovant (IMVT) CTO sells 2,754 shares in tax sell-to-cover - Stock Titan
Immunovant (IMVT) Innovation Pipeline | Immunovant posts 16.3% EPS beat on narrower lossRating Downgrade - Cổng thông tin điện tử tỉnh Lào Cai
Immunovant (NASDAQ:IMVT) Sets New 12-Month HighHere's What Happened - MarketBeat
How Immunovant Inc. (IMVT) Affects Rotational Strategy Timing - Stock Traders Daily
Immunovant Inc stock (US45258Q1058): Is its autoimmune pipeline strong enough to unlock new upside? - AD HOC NEWS
Immunovant: Best-In-Class Ambitions, Still Unproven (NASDAQ:IMVT) - Seeking Alpha
Immunovant Inc stock (US45258Q1058): Is its autoimmune pipeline strong enough to unlock biotech upsi - AD HOC NEWS
Immunovant (NASDAQ:IMVT) Reaches New 12-Month HighShould You Buy? - MarketBeat
Immunovant stock hits 52-week high at 29.26 USD By Investing.com - Investing.com Australia
Immunovant stock hits 52-week high at 29.26 USD - Investing.com
Piper Sandler Maintains Immunovant(IMVT.US) With Buy Rating, Raises Target Price to $66 - Moomoo
IMVT Maintained by Goldman Sachs -- Price Target Raised to $32 - GuruFocus
Generalized Myasthenia Gravis Market on the Brink of Change: 8 Promising Late-Stage Drugs Signal a New Treatment Era | DelveInsight - GlobeNewswire Inc.
LifeSci Capital Maintains Immunovant(IMVT.US) With Buy Rating, Maintains Target Price $42 - Moomoo
Elbit, Vor, Global-e, Sweetgreen, Immunovant: Insider Shake-Up - TipRanks
Immunovant (IMVT) CTO stout sells $251k in shares By Investing.com - Investing.com Canada
Van Tuyl, Immunovant’s chief legal officer, sells $128k in IMVT stock - Investing.com India
Insider Selling: Immunovant (NASDAQ:IMVT) Insider Sells 5,165 Shares of Stock - MarketBeat
Jay Stout Sells 10,132 Shares of Immunovant (NASDAQ:IMVT) Stock - MarketBeat
Immunovant (IMVT) CTO stout sells $251k in shares - Investing.com
Immunovant (IMVT) CLO sells 5,165 shares to cover RSU tax bill - Stock Titan
[Form 4] Immunovant, Inc. Insider Trading Activity - Stock Titan
Immunovant (NASDAQ: IMVT) CTO sells 10,132 shares for RSU tax obligations - Stock Titan
Immunovant Inc Azioni (IMVT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.14%
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):